Song Xiao-Chen, Wang Yong-Xue, Yu Mei, Cao Dong-Yan, Yang Jia-Xin
Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, National Clinical Research Center for Obstetrics & Gynecologic Diseases, Beijing, China.
Front Oncol. 2022 Mar 9;12:789228. doi: 10.3389/fonc.2022.789228. eCollection 2022.
Malignant transformations, such as ovarian squamous cell carcinoma (SCC) in ovarian mature cystic teratoma (OMCT), are rare tumors. The management of recurrent disease is still a challenge, and the gene mutations involved remain unclear. We herein report a recurrent case of ovarian SCC with a PIK3CA gene variation and immunohistochemical staining of programmed death-ligand 1 (PD-L1) >10%. This patient achieved clinical remission after platinum-based effective chemotherapy and programmed death 1 (PD-1) immunotherapy.
恶性转化，如卵巢成熟囊性畸胎瘤（OMCT）中的卵巢鳞状细胞癌（SCC），是罕见的肿瘤。复发性疾病的管理仍然是一项挑战，涉及的基因突变仍不清楚。我们在此报告一例复发性卵巢SCC病例，该病例存在PIK3CA基因变异，程序性死亡配体1（PD-L1）免疫组化染色>10%。该患者在铂类有效化疗和程序性死亡1（PD-1）免疫治疗后实现了临床缓解。
